Pharmathen – Double Materiality Assessment

Founded in 1969, Pharmathen has grown to become one of the largest, vertically integrated developers of complex drug delivery technologies. Pharmathen remains committed to its vision to improve people’s lives through innovation and access to affordable medicines. With best-in-class research & development capabilities, Pharmathen is currently working on one of the most extensive and advanced pipelines in the industry consisting of more than 40 products, with a focus on long-acting injectables (LAI), sustained release and ophthalmic formulations produced in its US FDA and EU approved manufacturing facilities in Greece. Pharmathen’s highly diversified product portfolio of more than 90 commercialized products is sold to 250 customers and accessed by patients in more than 90 countries worldwide.